Key facts
- This page summarizes Eric L. Keller's Form 4 filing for Retension Pharmaceuticals, Inc. (RTSN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 22 Oct 2026, 19:34.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. The option award was granted as a result of the underwriters' exercise of their over-allotment option on October 22, 2026 in connection with the Issuer's initial public offering, pursuant to the terms of the Reporting Person's Offer of Employment Letter with the Issuer, dated August 14, 2026. Twenty-five percent of the stock option vests on August 14, 2027, with the remaining stock options vesting in 36 monthly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.